ESR1 and breast cancer: Although miRNA-triggered downregulation of ERα expression can result in a decrease of its immunohistochemistry score, it does not totally suppress ERα levels, thus usually sustaining the “ER-positive” status of the respective BC tissue, allowing the use of ET regimens.